Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ENDRA Life Sciences (NDRA) just unveiled an update.
ENDRA Life Sciences, Inc. has partnered with Craig-Hallum Capital Group LLC to manage a public offering of over 6 million shares of common stock, warrants, and pre-funded warrants, closing with approximately $8 million in gross proceeds. The offering, completed on June 5, 2024, included common and pre-funded warrants paired with Series A and B warrants, with exercise prices set at $0.22. However, the warrants are subject to stockholder approval and a charter amendment to increase authorized shares. The deal also involves a 90-day lock-up period for company insiders and a cash plus stock compensation to the placement agent, with the company safeguarded against certain legal liabilities.
See more insights into NDRA stock on TipRanks’ Stock Analysis page.